A clinical trial to find a potential cure for Parkinson’s.

Currently there is an unmet clinical need to treat Parkinson Disease with Mild Cognitive Impairment (PD-MCI). In fact, nicotinic agonists are specifically relevant for this condition. Hence, the major aim of the project PD-MIND (Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug) is to identify the potential of the nicotinic α7 agonist AZD0328 in a randomized, placebo-controlled, parallel group, international multicentre study on cognitive function in people diagnosed with PD-MCI.

Arrow RightOur research

Share this page…